FORMULATION DEVELOPMENT, OPTIMIZATION & IN VITRO CHARATERIZATION OF LIQUISOLID COMPACTS OF AN OXICAM DERIVATIVE
Abstract
The rationale of the current research was to investigate the in vitro dissolution properties of poorly water soluble piroxicam by utilizing liquisolid technology. Dissimilar liquisoli compacts were formulated using a factorial design to estimate the required quantities of powder and liquid ingredients to fabricate adequately flowable and compressible admixture. About 16 different formulations were developed using factorial design with carriers Neusilin (Magnesium aluminometasilicate)Â and Avicel PH 102, binder PVP K-30 and vehicle PEG-400 as independent variables and Aerosil 200 is used as coating material. The In-vitro drug release from the LSC has used a dependent variable. The empirical method by Spireas and Bolton was applied to calculate the amounts of carrier and coating materials and obtained the improved flow characteristics and hardness by changing the proportion of carrier and coating materials. Liquid solid compacts were fabricated and evaluated for their tabletting properties. Fourier transform infrared (FTIR) analysis, differential scanning calorimetry (DSC) and X- ray powder diffraction (XRPD) were performed. The FTIR spectra showed disappearance of the characteristic absorption band of piroxicam (3338.78 cm-1) in liquisolid formulations which might be attributed to the formation of hydrogen bonding between the drug and liquid vehicle; this resulted in drug dissolution enhancement. A 23 factorial design is used and developed liquid soild compacts using Neusilin LSCN1 to LSCN8 and Avicel PH 102 LSCA1 to LSCA8. The physicochemical characterization of all formulations exhibited well within the specification limits with respect to weight variation, hardness, friability and content uniformity. Â The In-vitro drug release from these liquid soild compacts was evaluated in 0.1 N HCl and the optimized formulation LSCA8 was compared with pure drug (capsule) and physical mixture (tablet). The release studies suggested that the liquisolid tablets outcome in higher release profile than pure active pharmaceutical ingredient and physical mixture due to enhance in surface and wetting properties of the active pharmaceutical ingredient. Liquid solid compacts technique confirmed the enhanced dissolution rate of oxicam derivative, which in turn promotes in enhancing bioavailability.
Keywords: Piroxicam, Factorial design, Solubility, Dissolution rate, Avicel PH 102
DOI
https://doi.org/10.22270/jddt.v6i3.1263References
Prentis RA, Lis Y and Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985), British Journal of Clinical Pharmacology 1988; 25(3): 387-396.
Kapsi SG and Ayres JW. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. International Journal of Pharmaceutics 2001; 229: 1-2.
Javadzadeh Y, Jafari-Navimipour B, and Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine), International Journal of Pharmaceutics 2007: 341(1-2): 26-34.
Spireas S, Wang T. Grover R. Effect of powder substrate on the dissolution properties of methchrothiazide liquisolid compacts. Drug Dev. Ind. Pharm. 1999; 25 (2):163–168.
Nokhodchi A. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J. Pharm. Pharma. Sci 2005; 8 (1): 18–25.
Javadzadeh Y, Siahi-Shadbad M.R., Barzegar-Jalali M, Nokhodchi A. Enhancement of dissolution rate of piroxicam using liquisolid compacts. Il Farmaco. 2005; 60: 361–365.
Javadzadih Y, Stahi MR, Asnaashari S, Nokhodchi A. Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties. Acta Pharm 2007;57:99–109.
Vatyam JM, Vijaya Vani CS, Rao VU. Enhancement of solubility and dissolution rate of efavirenz using liquisolid compact technique. Int J Pharm 2014;4:150-6.
Christian L, Jennifer D. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47-60.
Kang MJ, Jung SY, Song WH, Park JS, Choi SU, Oh KT, et al. Immediate release of efavirenz from Fujicalin®-based fast-dissolving self-emulsifying tablets. Drug Dev Ind Pharm 2011;31:1298-305.
Naveen C, Shastri N, Tadikonda RR. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharm Sin B 2012;2:502-8.
Pratik Kumar A. Commercial telmisartan tablets: a comparative evaluation with innovator brand micardis pratik Kumar A. Int J Pharm Sci Res 2010;1:282-92.
Rajesh K, Raja Lakshmi R, Uma Maheswari J, Ashok Kumar C. Liquisolid technique a novel approach to enhance solubility and bioavailability. Int J Biopharm 2011; 2:8-13.
Raghavendra Gubbi S, Jarag R. Formulation and characterization of atorvastatin calcium liquisolid compacts. Asian J Pharm Sci 2010;5:50-60.
Spireas S, Bolton M. Liquisolid systems and methods of preparing same. U. S. Patent; 1999. p. 968, 550.
Tiong N, Elkordy AA. Effects of liquisolid formulations on the dissolution of naproxen. Eur J Pharm Biopharm 2009;73:373-84.
Vijay N, Ramarao T, Jaya Veera K. Liquisolid compacts a novel approach to enhance bioavailability of poorly soluble drugs. Int J Pharm Biol Sci 2011;1:89-102.
Wen X, Tan F, Jing Z, Liu Z. Preparation and study the 1:2 inclusion complex of carvedilol with beta-cyclodextrin. J Pharm Biomed Anal 2004;34:517-23.
Published
Abstract Display: 591 
PDF Downloads: 551 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.